UBC and partners sign major licensing deal with Roche

Guest Contributor
December 21, 2015

The Univ of British Columbia has completed its largest licensing agreement to date for a promising treatment for advanced prostate cancer. The agreement with Roche, a Basel, Switzerland-based multinational, was signed by UBC and the Vancouver Coastal Health Research Institute which co-host the Vancouver Prostate Centre where the new drug technology was developed and is now in pre-clinical development. Under the terms of the agreement, UBC and VCHRI will receive an upfront payment of up to US $141.7 million in pre-clinical, clinical and sales milestone payments. The scientists responsible for the development will share 50% of net revenues. The Vancouver Prostate Centre hosts PC-TRIADD, a Centre of Excellence for Commercialization and Research, which funded the research along with Prostate Centre Canada, Prostate Cancer Foundation, Safeway Canada and the Canadian Institute of Health Research's recently defunded Proof of Principle commercialization program....

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.